The FDA has approved Tibotec Pharmaceuticals' Prezista for treatment-resistant HIV patients. "One of the greatest challenges in HIV care is finding therapies for treatment-experienced patients," said Michael S. Saag, M.D., director of the AIDS Outpatient Clinic and the University of Alabama at Birmingham Center for AIDS Research. "This is an important new option for the thousands of people with HIV in the United States who are resistant to more than one protease inhibitor." Release